静脉侵袭的存在是乳头状甲状腺癌（PTC）复发中风险的一个标准。然而，静脉侵袭的存在和类型（淋巴性或静脉性）经常被低估，其对没有其他风险特征的PTC的影响仍然未知。本研究的目的是评估淋巴性和静脉性侵袭对否则风险低的PTC复发/持续风险的影响。回顾性研究包括2013年至2019年间诊断的否则风险低的PTC且有血管侵袭的患者。对随访期间的持续/复发进行评估。复审病理以确认淋巴血管侵袭的存在并确定侵袭类型。总共包括141位患者。20.6%的患者确认存在淋巴血管侵袭。手术后，48.9%（N=69）的患者接受了放射性碘治疗（RAI）。中位随访时间为4 [3-6]年。总体上，颈部有6位（4.2%）患者持续/复发疾病，其中3位确认为"只有淋巴性"的淋巴血管侵袭。总体上，相比没有淋巴血管侵袭的患者，肿瘤中存在淋巴血管侵袭的患者有着更高的持续/复发疾病风险（10.3%对2.7%，p=0.1），特别是在未接受RAI治疗的患者亚组中（20%对1.6%，p=0.049）[OR 15.25，95% CI 1.24-187.85，p=0.033]。淋巴血管侵袭，包括仅淋巴侵袭，与否则风险低的PTC持续/复发疾病的风险显著增加相关，尤其是在未接受RAI治疗的患者中。淋巴侵袭可能在风险分层系统中起到决策的角色。2023年。作者。

Presence of venous vascular invasion is a criterion of intermediate risk of recurrence in papillary thyroid carcinoma (PTC). However, the presence and type of vascular invasion (lymphatic or venous) is often underreported and its impact on PTCs without other risk features remains unknown. The aim of this study was to evaluate the impact of both lymphatic and venous invasion on the risk of recurrence/persistence on otherwise low-risk PTCs.Retrospective study including patients with otherwise low-risk PTCs but with vascular invasion, diagnosed between 2013 and 2019. The persistence/recurrence during the follow-up was evaluated. Pathology was reviewed to confirm the presence of lymphovascular invasion and determine the type of invasion.A total of 141 patients were included. Lymphovascular invasion was confirmed in 20.6%. After surgery, 48.9% (N = 69) of the patients received radioactive iodine (RAI). The median follow-up time was 4 [3-6] years. Overall, 6 (4.2%) patients experienced persistent/recurrent disease in the neck, including 3 with lymphovascular invasion, confirmed as "only lymphatic". Overall, patients with tumors harboring lymphovascular invasion had sensibly more persistent/recurrence disease compared with those without lymphovascular invasion (10.3% vs 2.7%, p = 0.1), especially in the subgroup of patients not treated with RAI (20% vs 1.6%, p = 0.049) [OR 15.25, 95% CI 1.24-187.85, p = 0.033].Lymphovascular invasion, including lymphatic invasion only, is associated with a sensibly higher risk of persistent/recurrent disease in otherwise low-risk PTCs, namely in patients not treated with RAI. Lymphatic invasion could have a role in risk-stratification systems for decision making.© 2023. The Author(s).